GALDY Other: a positive outcome, +0.9%

On February 12, 2025, Nemolizumab 30 mg — Galderma Group AG/ADR (Prurigo Nodularis) reached its Other. The result was a positive outcome, and the stock moved +0.9% in the window around the event. It had already run +17.0% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.